Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOCA vs FLUIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.
Fluidil is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis.
Adrenocortical insufficiency (Addison's disease),Salt-losing adrenogenital syndrome
Hypertension,Edema associated with congestive heart failure,Edema associated with renal disease,Edema associated with hepatic cirrhosis
Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.
5 mg orally once daily.
30-35 minutes; clinical context: short duration necessitates frequent dosing or continuous infusion for sustained effect.
Terminal elimination half-life: 1.5-2 hours (prolonged in hepatic impairment to 4-6 hours).
Primarily hepatic metabolism via reduction and conjugation; little is known about specific CYP enzymes.
Fluidil is extensively metabolized in the liver, primarily via glucuronidation and sulfation; cytochrome P450 enzymes play a minor role.
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible (<2%).
Renal: 60-70% unchanged; biliary/fecal: <5%; hepatic metabolism: 25-35%.
~70% bound to plasma proteins (primarily albumin).
85-92% bound to albumin, alpha-1-acid glycoprotein.
Vd: 0.8-1.2 L/kg; indicates extensive tissue distribution with rapid redistribution from effect sites.
0.8-1.2 L/kg (extensive tissue distribution).
Oral: <5% due to extensive first-pass metabolism; IM/SC: 100%.
Oral: 60-80% (first-pass metabolism).
No specific dose adjustment is recommended for impaired renal function, but monitor for fluid retention and hypertension. Use with caution in patients with significant renal impairment.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
No specific dose adjustment for hepatic impairment, but use with caution due to potential electrolyte disturbances.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 2.5 mg once daily. Child-Pugh Class C: not recommended.
Dose is not well established; use 0.1 to 0.2 mg/kg intramuscularly daily or adjust based on clinical response and serum electrolytes.
Not established for pediatric patients <18 years.
Start at the lower end of the dosing range (e.g., 1 to 2 mg IM daily) and monitor closely for fluid overload, hypertension, and electrolyte imbalances due to age-related decreased renal function and comorbidities.
No specific adjustment; use caution due to increased sensitivity.
None
No FDA black box warning has been issued for Fluidil.
Fluid overload and edema,Hypokalemia,Hypertension,Cardiac hypertrophy and failure,Increased risk of infection due to immune suppression when used with glucocorticoids
Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia),Hypovolemia and hypotension,Hyperuricemia and gout,Azotemia and renal impairment,Sulfonamide allergy cross-reactivity
Hypersensitivity to desoxycorticosterone or any component,Severe renal impairment,Hyperkalemia,Hypocalcemia,Congestive heart failure,Systemic fungal infections
Anuria,Hypersensitivity to Fluidil or other sulfonamide-derived drugs,Hepatic coma or pre-coma,Severe electrolyte depletion
No specific food interactions are reported. However, maintain consistent sodium intake; do not restrict salt unless advised. Avoid potassium-rich foods if potassium levels are high. Alcohol may increase the risk of electrolyte disturbances.
Avoid high-potassium foods (e.g., bananas, oranges, avocados, spinach, potatoes, salt substitutes with potassium chloride). Limit alcohol intake as it may worsen dizziness and dehydration. Grapefruit juice has not been reported to interact significantly, but caution is advised with other drugs. Maintain adequate fluid intake to prevent dehydration.
FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: risk of virilization of female fetuses; no adequate human studies; avoid use unless potential benefit outweighs risk.
FLUIDIL is contraindicated in pregnancy. First trimester: Associated with increased risk of major malformations, including neural tube defects and cardiac anomalies. Second and third trimesters: May cause oligohydramnios due to diminished fetal renal function; use may lead to fetal renal impairment, persistent ductus arteriosus, and craniofacial abnormalities.
Excreted in breast milk in low amounts; M/P ratio not established. Potential for adverse effects in nursing infants (e.g., electrolyte disturbances, hypertension). Use caution; consider alternative therapies.
Excreted in human milk; M/P ratio not established. Use is not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants.
No specific dose adjustments studied; monitor for increased volume of distribution and clearance; adjust based on clinical response and serum electrolyte levels. Use lowest effective dose.
FLUIDIL is not indicated for use in pregnancy. No dosage adjustment recommendations are available for pregnant women; avoidance is mandatory.
DOCA (desoxycorticosterone acetate) is a mineralocorticoid used in adrenal insufficiency. Monitor serum potassium closely due to risk of hypokalemia from excessive mineralocorticoid activity. DOCA requires intramuscular injection; do not administer intravenously. Use in conjunction with glucocorticoids to mimic cortisol's permissive effects on catecholamines. Avoid in patients with hypertension, heart failure, or renal impairment due to sodium and water retention.
Fluidil (a diuretic combination, e.g., hydrochlorothiazide and triamterene) may cause electrolyte disturbances; monitor potassium levels closely due to triamterene's potassium-sparing effect. Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min) or hyperkalemia. Onset of diuresis occurs within 2 hours, peak effect at 4-6 hours. Administer in the morning to prevent nocturia.
This medication helps maintain salt and water balance in the body.,It is given as an injection into a muscle; do not inject into a vein.,Report signs of excessive fluid retention: swelling in legs, rapid weight gain, shortness of breath.,Monitor for muscle cramps or weakness which may indicate low potassium levels.,Avoid salt substitutes containing potassium without consulting your doctor.,Do not miss appointments for injections as consistent dosing is critical.,Carry medical identification indicating you take corticosteroid replacement therapy.
Take this medication in the morning to reduce nighttime urination.,Avoid potassium supplements or high-potassium foods (e.g., bananas, oranges, salt substitutes) unless directed by your doctor.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst.,Stay hydrated but avoid excessive fluid intake; drink water as needed.,Report any rash, difficulty breathing, or swelling of the face/lips immediately.,Do not drive or operate machinery if you feel dizzy or lightheaded, especially during the first few days of treatment.
"Lidocaine, a sodium channel blocker and Class IB antiarrhythmic, inhibits hepatic CYP3A4, the primary enzyme responsible for the metabolism of quazepam, a benzodiazepine sedative-hypnotic. This inhibition reduces quazepam clearance, leading to elevated serum concentrations and enhanced sedative effects. Clinically, this may result in excessive sedation, respiratory depression, psychomotor impairment, and increased risk of falls, especially in elderly patients or those with hepatic impairment."
"Lidocaine and prilocaine are both amide-type local anesthetics that block voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse propagation. When used together, their systemic absorption can lead to additive cardiovascular and central nervous system toxicity, including arrhythmias, seizures, and methemoglobinemia, particularly with high doses or in patients with predisposing conditions."
"Lidocaine, a class Ib antiarrhythmic, inhibits CYP3A4, the primary enzyme responsible for the metabolism of ticagrelor, a P2Y12 platelet inhibitor. This inhibition can lead to increased plasma concentrations of ticagrelor, potentiating its antiplatelet effect and elevating the risk of major bleeding, such as gastrointestinal or intracranial hemorrhage. Conversely, reduced ticagrelor metabolism may also affect conversion to its active metabolite, though net effect still increases overall antiplatelet activity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOCA vs FLUIDIL, answered by our medical review team.
DOCA is a Mineralocorticoid that works by Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.. FLUIDIL is a Mineralocorticoid that works by Fluidil is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOCA and FLUIDIL depend on the specific clinical indication. These are both Mineralocorticoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOCA is: Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.. The standard adult dose of FLUIDIL is: 5 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOCA and FLUIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOCA is classified as Category C. FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: ri. FLUIDIL is classified as Category C. FLUIDIL is contraindicated in pregnancy. First trimester: Associated with increased risk of major malformations, including neural tube defects and cardiac anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.